Evidence map›Paper›PMID 39412222›Full record

ArticleAging cell2025

Altered tubulin detyrosination due to SVBP malfunction induces cytokinesis failure and senescence, underlying a complex hereditary spastic paraplegia.

Nathalie Launay, Maria Espinosa-Alcantud, Edgard Verdura, Gorka Fernández-Eulate, Jon Ondaro, Pablo Iruzubieta, Maria Marsal, Agatha Schlüter, Montserrat Ruiz, Stephane Fourcade and 8 more

Abstract read
In one paragraph

Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nathalie LaunayNeurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
Maria Espinosa-AlcantudChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute, Badalona, Spain.
Edgard VerduraNeurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
Gorka Fernández-EulateNord-Est/Ile-de-France Neuromuscular Reference Center, Institute of Myology, Pitié-Salpêtrière Hospital, Paris, France.
Jon OndaroDepartment of Neurosciences, Instituto Biodonostia, San Sebastián, Spain.
Pablo IruzubietaDepartment of Neurology, Hospital Universitario Donostia, OSAKIDETZA-Department of Neurosciences, University of the Basque Cpuntry, San Sebastian, Spain.
Maria MarsalICFO-Institut de Ciencies Fotoniques, The Barcelona Institute of Science and Technology, Castelldefels, Spain.
Agatha SchlüterNeurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
Montserrat RuizNeurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
Stephane FourcadeNeurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
Agustí Rodríguez-PalmeroNeurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
Miren ZulaicaDepartment of Neurosciences, Instituto Biodonostia, San Sebastián, Spain.
Andone SistiagaCenter of Biomedical Research in Neurodegenerative Diseases (CIBERNED), CIBER, Ministry of Science, Innovation and University, Madrid, Spain.
Garazi LabayruCenter of Biomedical Research in Neurodegenerative Diseases (CIBERNED), CIBER, Ministry of Science, Innovation and University, Madrid, Spain.
Pablo Loza-AlvarezICFO-Institut de Ciencies Fotoniques, The Barcelona Institute of Science and Technology, Castelldefels, Spain.
Alejandro VaqueroChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute, Badalona, Spain.ORCID 0000-0002-8735-4156
Adolfo Lopez de MunainDepartment of Neurology, Hospital Universitario Donostia, OSAKIDETZA-Department of Neurosciences, University of the Basque Cpuntry, San Sebastian, Spain.
Aurora PujolNeurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.ORCID 0000-0002-9606-0600

Funding

Association ASL-HSP and 'La Marató de TV3' Foundation 202006-30Catalan government agency AGAUR AGAUR 2021-SGR-01378Centre for Biomedical Research on Rare Diseases (CIBERER) ACCI19-759Fundación Hesperia and Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia 2017SGR1206Instituto de Salud Carlos III CD19/00221Instituto de Salud Carlos III Miguel Servet program CP11/00080the Spanish Ministry of Economy and Competitiveness MINECO BES-2015-071251the Spanish Ministry of Economy and Competitiveness MINECO PID2020-117284RB-100the Spanish Ministry of Economy and Competitiveness MINECO SEV-2015-0522URDcat programme PERIS SLT002/16/00174
6 · The paper itself

Abstract

Senescence, marked by permanent cell cycle arrest may contribute to the decline in regenerative potential and neuronal function, thereby promoting neurodegenerative disorders. In this study, we employed whole exome sequencing to identify a previously unreported biallelic missense variant in SVBP (p.Leu49Pro) in six patients from three unrelated families. These affected individuals present with a complex hereditary spastic paraplegia (HSP), peripheral neuropathy, verbal apraxia, and intellectual disability, exhibiting a milder phenotype compared to patients with nonsense SVBP mutations described previously. Consistent with SVBP's primary role as a chaperone necessary for VASH-mediated tubulin detyrosination, both patient fibroblasts with the p.Leu49Pro mutation, and HeLa cells harboring an SVBP knockdown exhibit microtubule dynamic instability and alterations in pericentriolar material (PCM) component trafficking and centrosome cohesion. In patient fibroblasts, structural abnormalities in the centrosome trigger mitotic errors and cellular senescence. Notably, premature senescence characterized by elevated levels of p16INK4, was also observed in patient peripheral blood mononuclear cells (PBMCs). Taken together, our findings underscore the critical role of SVBP in the development and maintenance of the central nervous system, providing novel insights associating cytokinesis failure with cortical motor neuron disease and intellectual disability.

Indexed as

Cellular SenescenceCytokinesisSpastic Paraplegia, HereditaryTubulinAdultFemaleHumansMaleTubulincentrosomecytokinesis failureHSPmicrotubule detyrosinationsenescenceSVBP

Identifiers

PMID39412222
PMCPMC11709099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.